Earlier this month, Merck and Daiichi Sankyo announced that ifinatamab deruxtecan was granted Breakthrough Therapy Designation by the U.S. FDA for treating adult patients with extensive-stage small ...

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

Merck MRK announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd ...

Ifinatamab deruxtecan has been granted Breakthrough Therapy Designation by the FDA for the treatment of adult patients with extensive-stage small ...

Rahway: Merck and Daiichi Sankyo have announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy ...

AbbVie’s oncology segment generated combined revenues of $3.3 billion in the first half of 2025, rising 4.2% year over year ...

On Oct. 19, narrow-moat Daiichi Sankyo announced an out-licensing deal with Merck for three of Daiichi’s antibody-drug conjugate candidates. The total up-front payments are $5.5 billion, up to ...

The treatment is one of three antibody-drug conjugates (ADCs) included in Merck's up to $22-billion joint development and commercialization deal with Daiichi Sankyo, signed last year.

Merck & Co. and Daiichi Sankyo on Tuesday said one of the drug candidates in their multibillion-dollar collaboration has hit its main goal in a late-stage lung-cancer study.

Merck (MRK) and Daiichi Sankyo's (DSNKY) lung cancer drug, patritumab deruxtecan hits the primary endpoint in a Phase 3 trial as a second-line therapy. Read more here.

(RTTNews) - Daiichi Sankyo Company Limited (DSKYF.PK) and Merck & Co Inc. (MRK) Tuesday said they have expanded their development and commercialization agreement to include Merck's MK-6070, an ...

Sept 17 (Reuters) - Daiichi Sankyo (4568.T) and Merck (MRK.N) said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some patients with a form of lung ...